Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced
today that the Company will web cast its Annual General Meeting in
Toronto on Tuesday, May 10, 2005 at 10:00 a.m. EDT. The web cast will
include corporate and scientific updates. The web cast will be
chaired by Dr. Robert Foster, Chairman and CEO; with Dr. Randall
Yatscoff, President and COO presenting the scientific update.
Interested parties can access the live web cast by logging on to
or through the Company's Web site at www.isotechnika.com. A recording
of the web cast will be archived for a 180 day period through the web
cast archives at www.newswire.ca and on the Company's Web site
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant
currently in a Canadian Phase III human clinical trial for the
treatment of moderate to severe psoriasis. In addition, ISA247 has
successfully completed a Phase IIa trial for kidney transplantation.
The Company also has two additional immunosuppressive compounds in
its drug pipeline, TAFA93 and TKB662 which are in Phase I and
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(R) and Diatest(R)
breath kits. The Helikit(R) a (13)C urea breath test is used for the
detection of H. pylori, a bacterium that infects a large portion of
the population. The Diatest(R) a (13)C glucose breath test is used to
measure insulin resistance.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
This press release may contain forward-looking statements.
Forward-looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements.
Archived images on this organization are searchable through CNW
Photo Archive website at http://photos.newswire.ca. Images are free
to accredited members of the media. To request a free copy of this
organization's annual report, please go to http://www.newswire.ca and
click on reports@cnw.: Isotechnika Inc.
ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.ch
For further information: Stephanie Gillis-Paulgaard, Senior Manager,
Corporate Communications & Investor Relations, Isotechnika Inc.,
Phone: +1-780-487-1600 extension 243, Fax: +1-780-484-4105, E-mail: